Circulating vitamin D concentration and risk of prostate cancer: a dose–response meta-analysis of prospective studies
Therapeutics and Clinical Risk Management, 9 January 2018 Vol 2018:14 Pages 95—104, DOI https://doi.org/10.2147/TCRM.S149325
Gao JL, Wei W, Wang G, Zhou HL, Fu YW, Liu N
Department of Urology, The First Hospital of Jilin University, Changchun, People’s Republic of China
| Studies | Risk increase per 10 ng |
| Before 2010 | 3% |
| Since 2010 | 6% |
| Which adjusted for excess Calcium | 10% |
See also VitaminDWiki
- Cancer - Prostate category listing has
103 items along with related searches - Prostate Cancer long term survival 1.7 X more likely if high level of vitamin D – Jan 2016
- 7X increase in stage IV Prostate Cancer survival when vitamin D greater than 32 ng – May 2013
- Prostate cancer reduced when 4000 IU vitamin D was added– Hollis RCT April 2015
- Prostate Cancer treatment (Vitamin D, Omega-3, Tumeric) RCT ending Dec 2018
The Meta-analysis of Prostate Cancer and Vitamin D
- 1.5X more likely to die of Prostate Cancer if low vitamin D when initially diagnosed – meta-analysis March 2024
- Deaths from many types of Cancer associated with low vitamin D- review of meta-analyses Sept 2020
- Variety of Vitamin D forms treat Prostate Cancer – RCT Review April 2019
- Prostate Cancer death 40 percent less likely if 40 ng level of vitamin D – Meta-analysis Oct 2018
- Prostate cancer risk increase with Vitamin D (other studies disagree) – meta-analysis Jan 2018
- Meta-graphs of vitamin D and Cancer – Dec 2011
- Risk of Prostate Cancer weakly associated with vitamin D - meta-analysis March 2011
- 16 percent less Prostate Cancer sometimes for each 10 ng vitamin D increase - meta-analysis Jan 2011
- Meta-analysis found vitamin D association with colon but not prostate nor breast cancer May 2010
Pages listed in both of the categories Prostate Cancer and Calcium
Download the PDF from VitaminDWiki
Risk for all studies (not adjusted for excess Calcium)
Background: Though many studies have been performed to elucidate the association between circulating vitamin D and prostate cancer, no conclusive result is available. We carried out a dose–response meta-analysis to quantitatively examine the association of circulating 25-hydroxyvitamin D (25[OH]D) concentration with prostate cancer.
Methods: Only prospective studies examining the associations of circulating 25[OH]D concentration with prostate cancer were eligible for the meta-analysis. A random-effect meta-analysis was done first, to calculate the summary relative risk (RR) and 95% confidence intervals (CIs) comparing the higher concentration with the lower concentration of 25[OH]D. A dose–response meta-analysis using random-effects model was then carried out to evaluate the nonlinearity and calculate the summary RR caused per 10 ng/mL increment.
Results: Nineteen prospective cohort or nested case–control studies were included. Higher 25[OH]D concentration was significantly correlated with elevated risk of prostate cancer (RR =1.15, 95% CI 1.06–1.24). No nonlinear relationship was found between 25[OH]D concentration and risk of prostate cancer (P=0.654). Dose–response meta-analysis showed that the summary RR caused per 10 ng/mL increment in circulating 25[OH]D concentration was 1.04 (95% CI 1.02–1.06). Subgroup analysis also found a modest dose–response relationship. Funnel plot and Egger’s test did not detect publication bias.
Conclusion: The findings suggest that highest 25[OH]D concentration is correlated with elevated risk of prostate cancer and a modest dose–response effect exists in this association; however, more studies are needed.
Printer Friendly Follow this page for updates5839 visitors, last modified 21 Oct, 2021,